Correction to: Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (Current Oncology, (2023), 30, 7, (6097-6110), 10.3390/curroncol30070454)